The Amsterdam facility will include a cryogenic filling station to meet the growing need of Marken's cell and gene therapy clients. An additional LN2 service station has been added to Marken's network in Geneva, Switzerland.
"The infrastructure investments we have made in all of our facilities globally serve a single purpose," said Ariette van Strien, president, Marken. "Since 2011, we have made investments which meet client demands where they need us. Marken will always strive to offer the very best service, reliability and security for our clients."
By early Q4, Marken will have 12 fully operational GMP-compliant depot locations, complemented by more than 10 million square feet of GMP-validated commercial warehouse space in 56 UPS Healthcare distribution centers. This extensive global network provides an exceptional degree of flexibility and efficiency, whether it involves coordinating supplies from a central or regional location based on trial enrollment activity or implementing innovative strategies that are built for future demand.
Wes Wheeler, president, UPS Healthcare, said, "Marken continues to lead as our clinical trial logistics subsidiary with unique new services and a very broad reach. We will continue to invest in Marken as the industry moves into new regions of the world, becomes more virtual, and demands a greater degree of control and visibility. We are also using their unique knowledge in clinical trials to influence our strategic investments in healthcare."